LifeMD, Inc. (NASDAQ:LFMD) Given Consensus Rating of “Buy” by Analysts

Shares of LifeMD, Inc. (NASDAQ:LFMD) have received a consensus recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have covered the stock in the last year is $12.00.

Several brokerages have recently commented on LFMD. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of LifeMD in a research note on Monday, November 11th. B. Riley started coverage on shares of LifeMD in a research report on Friday, August 23rd. They set a “buy” rating and a $11.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $15.00 target price on shares of LifeMD in a report on Friday, September 20th.

LifeMD Stock Down 2.0 %

Shares of LifeMD stock opened at $6.34 on Wednesday. The stock has a 50-day simple moving average of $5.06 and a 200-day simple moving average of $6.08. LifeMD has a 52-week low of $3.99 and a 52-week high of $12.88. The firm has a market cap of $274.59 million, a price-to-earnings ratio of -9.91 and a beta of 1.23. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.83 and a quick ratio of 0.78.

Institutional Investors Weigh In On LifeMD

A number of hedge funds have recently bought and sold shares of LFMD. State Street Corp grew its holdings in LifeMD by 20.0% in the 3rd quarter. State Street Corp now owns 1,155,495 shares of the company’s stock valued at $6,055,000 after buying an additional 192,861 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of LifeMD by 12.5% in the first quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock worth $11,875,000 after acquiring an additional 128,701 shares during the last quarter. Royce & Associates LP increased its position in LifeMD by 14.6% during the third quarter. Royce & Associates LP now owns 901,041 shares of the company’s stock worth $4,721,000 after acquiring an additional 114,710 shares during the period. Los Angeles Capital Management LLC raised its stake in LifeMD by 852.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock valued at $637,000 after purchasing an additional 108,822 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in LifeMD by 63.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company’s stock valued at $1,609,000 after purchasing an additional 91,183 shares during the period. 35.52% of the stock is currently owned by institutional investors.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.